Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ranibizumab

ranibizumab

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ranibizumab

90 trials tracked of ranibizumab: 49 in phase 3 or 4 and 12 with published results. The most-cited published study has 443 citations.

90Trials tracked
49Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 15 Phase 3 34 Phase 2 34 Phase 1 6 Other / NA 1
  1. Phase 3 RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity Completed · 443 cited
  2. Phase 4 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) Completed · 297 cited
  3. Phase 3 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed · 119 cited
  4. Phase 4 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) Completed · 100 cited
  5. Phase 3 Rainbow Extension Study Completed · 93 cited
  6. Phase 4 Study EvAluating Genotypes While Using Lucentis 2 Completed · 38 cited
Show 44 more trials
  1. Phase 4 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed · 28 cited
  2. Phase 4 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed · 20 cited
  3. Phase 3 Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration Completed · 9 cited
  4. Phase 3 Lucentis (Ranibizumab) for Eales' Disease Completed · 6 cited
  5. Phase 3 A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) Completed · 4 cited
  6. Phase 3 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Completed · 1 cited
  7. Phase 4 Head to Head Study of Anti-VEGF Treatment. Completed
  8. Phase 4 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed
  9. Phase 4 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed
  10. Phase 4 Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed
  11. Phase 4 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Completed
  12. Phase 4 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed
  13. Phase 4 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed
  14. Phase 4 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed
  15. Phase 4 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed
  16. Phase 4 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed
  17. Phase 3 To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema Completed
  18. Phase 3 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Completed
  19. Phase 3 Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye Completed
  20. Phase 3 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed
  21. Phase 3 A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration Completed
  22. Phase 3 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration Completed
  23. Phase 3 Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration Completed
  24. Phase 3 Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD Completed
  25. Phase 3 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Completed
  26. Phase 3 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Completed
  27. Phase 3 Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) Completed
  28. Phase 3 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed
  29. Phase 3 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
  30. Phase 3 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) Completed
  31. Phase 3 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) Completed
  32. Phase 3 A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study Completed
  33. Phase 3 Lucentis Versus Mitomycin C During Glaucoma Surgery Completed
  34. Phase 3 Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Completed
  35. Phase 3 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Completed
  36. Phase 3 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Completed
  37. Phase 3 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed
  38. Phase 3 Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) Completed
  39. Phase 3 SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Completed
  40. Phase 3 Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  41. Phase 3 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed
  42. Phase 3 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) Completed
  43. Phase 3 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed
  44. Phase 2 Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) Completed

Showing the 50 most-cited and recently-updated of 90 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ranibizumab port delivery system shows noninferior BCVA gains and low supplemental treatment requirements in diabetic retinopathy
Oncology Meta-analysis
Ranibizumab port delivery system shows noninferior BCVA gains and low supplemental treatment requirements in diabetic retinopathy Ranibizumab port delivery system shows promise for diabetic eye conditions
This meta-analysis evaluates the ranibizumab port delivery system (PDS) for patients with diabetic retinopathy and diabetic macular edema. T…
A new delivery system for ranibizumab shows consistent results for patients with diabetic retinopathy and macular edema.
Aug 28, 2026
Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits
Oncology RCT
Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits Radiotherapy Shows Potential Cost Savings for Macular Degeneration Patients
Researchers evaluated the impact of stereotactic radiotherapy alongside ranibizumab for patients with neovascular age-related macular degene…
A trial suggests that adding stereotactic radiotherapy to standard care may lower healthcare costs and help track quality of life in macular…
Aug 26, 2026
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity
Ophthalmology Meta-analysis
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity Faricimab shows better vision outcomes for age related macular degeneration
This meta-analysis of 8 studies involving 8458 study populations found that faricimab 6 mg every sixteen weeks showed superior effects on be…
A new treatment option for age related macular degeneration may offer better vision and thinner retinal tissue than current standard drugs.
Aug 4, 2026
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion
Oncology Meta-analysis
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion Eye Drug Comparison Shows Similar Vision Gains
This meta-analysis of 759 patients with RVO-ME found no significant difference between intravitreal ranibizumab and bevacizumab monotherapy …
Two common eye injections work equally well for swelling caused by retinal vein blockage, a new analysis finds.
Aug 1, 2026
Carbonic anhydrase inhibitors and DEXi show superior CMT reduction in retinitis pigmentosa macular oedema
Ophthalmology Sys. Review
Carbonic anhydrase inhibitors and DEXi show superior CMT reduction in retinitis pigmentosa macular oedema New Analysis Compares Treatments for Retinitis Pigmentosa Macular Oedema
This network meta-analysis evaluates various treatments for retinitis pigmentosa (RP)-associated macular oedema. The study found that carbon…
Different medications show varying success in reducing swelling and improving vision for patients with retinitis pigmentosa-associated macul…
Jul 24, 2026
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Orthopedics & Sports Medicine Guideline
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
Frontiers May 8, 2026
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Ophthalmology Meta-analysis
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
May 1, 2026
Lower vitreous CREG1 levels associated with reduced ranibizumab response in diabetic macular edema
Rheumatology Cohort
Lower vitreous CREG1 levels associated with reduced ranibizumab response in diabetic macular edema Low CREG1 levels may link to poor treatment response
This retrospective cohort study of 189 patients with diabetic macular edema found that lower vitreous CREG1 levels were associated with non-…
New findings suggest that certain protein levels and blood markers might help identify which patients respond to diabetic macular edema trea…
Frontiers Apr 30, 2026
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy
Rheumatology Cohort
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy Adding Laser to Eye Injections Cuts Treatment Burden for Diabetic Eye Disease
This retrospective cohort study included 238 patients with proliferative diabetic retinopathy.
Combining injections with laser treatment for diabetic eye disease significantly reduces future procedures and complications while preservin…
Frontiers Apr 28, 2026
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
Ophthalmology Meta-analysis
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
Frontiers Apr 4, 2026
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
Drug Pipeline FDA Approval
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
FDA Apr 2, 2026
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Ophthalmology Meta-analysis
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Apr 2, 2026

All ranibizumab Articles